高度糖化最终产品 碳氧甲基和老年人心力衰竭和心房
Yakubu Bene-Alhasan1,2, Traci M Bartz3, Luc Djoussé4
1Section of Cardiovascular Research, Department of Medicine Baylor College of Medicine Houston TX USA.
Journal of the American Heart Association
|September 6, 2025
概括
血清Nε- carboxymethyl- lysine (CML) 是高级糖化最终产品 (AGEs) 的标记物,与老年人心力衰竭 (HF) 和心房动 (AF) 的风险增加有关. 建议对AGE和相关疗法的进一步研究.
科学领域:
- 心血管科学
- 老龄化研究
- 代谢疾病
背景情况:
- 高度糖化最终产物 (AGEs) 由高血糖和氧化应激产生的,影响血管和心脏健康.
- AGEs改变心血管结构和功能,但它们与心力衰竭 (HF) 和心房动 (AF) 的联系尚未得到充分研究.
- Nε- 碳糖甲氨酸 (CML) 是一个关键的AGE,与年龄相关的心血管变化有关.
研究的目的:
- 在老年人中研究血清CML水平与发生的HF和AF之间的潜在关联.
- 检查与HF亚型和心声表型的二次关联.
- 探索影响CML-HF和CML-AF关系的潜在调解因素.
主要方法:
- 使用来自心血管健康研究 (CHS) 的数据,这是一组基于人口的老年人.
- 在2685名参与者中使用免疫测试测量血清CML.
- 随访参与者平均9年,以确定发生的HF和AF事件.
主要成果:
- 在混调整后,血清CML升高与发生HF (HR 1. 10) 和AF (HR 1.09) 的风险增加有关.
- 通过对功能标志物 (eGFR,UACR) 的调整减弱了AF相关性.
- 在调整心肌梗塞时,HF相关性减弱;在调整 natriuretic时,这两种相关性都变得无意义.
结论:
- 在老年人中,血清CML与HF和AF风险的增加有前性关联,独立于许多混因素.
- 这些关联部分归因于功能,心肌梗塞和尿酸.
- 在预防心血管疾病方面,需要进一步研究AGE和针对AGE的疗法.
相关概念视频
01:30Coronary Artery Disease I: Introduction
54
Coronary Artery Disease (CAD): An Overview with Scientific InsightsCoronary Artery Disease (CAD), often referred to as C-A-D, is a prevalent blood vessel disorder classified under the broader category of atherosclerosis. Atherosclerosis is a pathological process characterized by the hardening and narrowing of arteries due to the accumulation of atherosclerotic plaques. These plaques are composed of cholesterol, fatty substances, inflammatory cells, calcium, and fibrin, reducing blood flow to...
54
01:27Heart Failure I: Introduction
49
Heart failure refers to a clinical syndrome caused by structural or functional cardiac disorders that prevent the heart from pumping an adequate amount of blood to meet the body's metabolic needs. This condition often arises from myocardial infarction or ischemia, leading to decreased cardiac output, reduced tissue perfusion, impaired gas exchange, fluid volume imbalance, and decreased functional ability.Heart failure can result from disruptions in the mechanisms that regulate cardiac output...
49
01:29Heart Failure II: Pathophysiology
33
Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
33
01:17Pathophysiology of Heart Failure
1.8K
Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
1.8K
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
505
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
505
01:26Atherosclerosis III: Management
33
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
33